Telix Pharmaceuticals (TLX) Receivables - Other (2023 - 2025)

Telix Pharmaceuticals (TLX) has reported Receivables - Other for 3 consecutive years, with $1.3 million the latest figure, recorded in Q4 2025.

• Quarterly Receivables - Other fell 29.96% year-over-year to $1.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.3 million (down 29.96% YoY) and the FY2025 annual result came in at $1.3 million, down 27.22% from the prior year.
• Receivables - Other declined to $1.3 million in Q4 2025 per TLX's latest filing, from $1.8 million in the prior quarter.
• Over the last five years, Receivables - Other for TLX reached as high as $1.8 million in Q4 2024 and fell as low as $1.3 million in Q4 2025.
• A 3-year average of $1.6 million and a median of $1.7 million in 2023 frame the typical range for Receivables - Other.
• Annual changes were most pronounced in 2024 — Receivables - Other rose 10.03% — and 2025, when it fell 29.96%.
• Year by year, Receivables - Other stood at $1.7 million in 2023, then climbed by 10.03% to $1.8 million in 2024, then retreated by 29.96% to $1.3 million in 2025.
• According to Business Quant data, Receivables - Other over the past three periods registered $1.3 million, $1.8 million, and $1.7 million for Q4 2025, Q4 2024, and Q4 2023 respectively.